New contamination-detection test to improve T-cell therapy
Method to improve sterility assurance in biopharmaceutic manufacturing will lead to better patient outcomes.
List view / Grid view
Method to improve sterility assurance in biopharmaceutic manufacturing will lead to better patient outcomes.
Findings of rare CRISPR-linked gene modules and a novel CRISPR-Cas system have promising implications for genomic therapeutics.
US researchers find that a modified immune protein harming brain connections is much more common in the brains of women with Alzheimer’s, compared to men.
A capsule that tunnels through mucus in the gastrointestinal tract could be used to orally administer large protein drugs such as insulin.
A geometric deep-learning model is faster and more accurate than state-of-the-art computational models, reducing the chances and costs of drug trial failures.
Researchers at Synlogic are clearing the path for a new class of medicine – biotherapeutics based on synthetic biology, called synthetic biotics, which are created by programming or engineering bacteria to metabolise or secrete well-validated targets of disease pathophysiology. In this article, Dr Caroline Kurtz, Chief Development Officer at Synlogic, discusses how synthetic…
Researchers have developed a novel microscopy technique to make invisible molecules visible by “de-crowding” to expand a cell or tissue sample before labelling the molecules.
A new insight into the way the EGF receptor sends signals into cells could help researchers design new cancer drugs that target this protein.
Targeting these brain circuits could offer a new way to reverse motor dysfunction and depression in Parkinson’s disease patients.
Tested using a new brain tissue model, researchers have developed nanoparticles which may be able to deliver chemotherapy drugs for glioblastoma.
New machine learning models could propose new molecules that have specific properties which could fight certain diseases, doing in minutes what might take humans months to achieve manually.
MIT chemists have discovered a possible way to design drugs that could fight against drug resistance.
Scientists identified three prototypical RNA-expression states and revealed differences in their susceptibility to a variety of cancer drugs.
The new research shows how interleukin-17a (IL-17a) can alter the trajectory of immune system development and cause gut inflammation.
The new nanoparticle adjuvant improved antibody production following vaccination against HIV, diphtheria and influenza in mouse models.